STOCK TITAN

Dyadic International, Inc. - DYAI STOCK NEWS

Welcome to our dedicated page for Dyadic International news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic International stock.

Dyadic International, Inc. (OTCQX: DYAI) is a global biotechnology company renowned for its pioneering work in gene expression systems. The company has developed the C1 Expression System, a patented and proprietary technology utilizing the Thermothelomyces heterothallica fungus, which has set new standards in the production of commercial quantities of industrial enzymes and other proteins. This innovative platform is licensed to industry giants like Abengoa Bioenergy, BASF, and Codexis for various non-pharmaceutical applications.

Core Business
Dyadic's core business revolves around the advancement and application of the C1 Expression System. This platform is instrumental in producing biologic vaccines and drugs at a faster rate, in larger volumes, and at a lower cost, thereby making healthcare more accessible and affordable. By enhancing protein production capabilities, Dyadic aims to meet the growing demands of drug developers and manufacturers, ultimately improving patient care and saving lives.

Recent Achievements and Current Projects
Dyadic has made significant strides in the biotechnology sector. The company has successfully showcased the efficiency of the C1 Expression System in various industrial applications. Currently, Dyadic is focusing on expanding its influence in the pharmaceutical sector, aiming to leverage C1's potential for large-scale production of human and animal vaccines and therapeutics.

Financial Condition
With a solid financial foundation, Dyadic continues to invest in research and development, ensuring the continuous improvement of its gene expression technology. The company's partnerships and licensing agreements with major industry players underscore its financial stability and growth potential.

Partnerships and Collaborations
Dyadic's collaborative efforts with companies like Abengoa Bioenergy, BASF, and Codexis highlight its pivotal role in the biotechnology landscape. These partnerships enable Dyadic to expand the application of the C1 Expression System beyond pharmaceuticals, touching sectors such as food, nutrition, and wellness.

Products and Services
Dyadic's primary product, the C1 Expression System, is a game-changer in gene expression and protein production. The company is dedicated to advancing this technology to meet the evolving needs of the biopharmaceutical industry, ensuring more efficient and cost-effective production processes.

Contact Information
For further information, inquiries can be directed to Ping W. Rawson, Chief Financial Officer, at (561) 743-8333 or via email at ir@dyadic.com.

Rhea-AI Summary

Dyadic International (NASDAQ: DYAI) has expanded its licensing agreement with Rubic One Health to enhance the development and distribution of vaccines and biologics for human and animal health in Africa. This agreement builds on a previous collaboration focused on COVID-19 vaccines and now encompasses a wider range of therapeutic proteins beyond COVID-19.

As part of the deal, Dyadic will gain marketing rights and receive milestone and royalty payments from Rubic. The partnership aims to leverage Dyadic’s C1-cell protein expression platform, which is noted for its efficiency in production and reduced costs, to address the unmet healthcare needs in underserved regions.

CEO Mark Emalfarb highlighted the advantages of their C1 technology while Rubic's CEO Dr. Julian Naidoo emphasized the importance of this collaboration for Africa’s healthcare capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
-
Rhea-AI Summary

Dyadic International (NASDAQ: DYAI), a biotechnology company, announced its CEO, Mark Emalfarb, will present at the World Vaccine Congress in Washington, D.C. from April 4-6, 2023. Emalfarb's presentation, scheduled for April 5, will focus on transforming manufacturing and bridging technology gaps in vaccine production.

Additionally, he will provide an update on the Phase 1 Clinical Trial for the DYAI-100 COVID-19 vaccine. Key trial milestones include completing dosing in February 2023, with no serious adverse events reported and a full study report expected in the second half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.13%
Tags
conferences
-
Rhea-AI Summary

Dyadic International (NASDAQ: DYAI) has received regulatory approval for its Phase 1 trial of the DYAI-100 COVID-19 booster vaccine. The trial has successfully completed dosing for both low and high groups with no serious adverse events reported. The company reported a 21.9% year-over-year revenue increase for 2022, reaching approximately $2.93 million. Dyadic maintains cash and investments of $12.7 million, sufficient to fund operations into 2024. Significant collaborations with Janssen, Hengrui, and Phibro have been established, alongside the initiation of the Dapibus™ platform for microbial protein production. A conference call discussing financial results is scheduled for today at 5 PM ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.13%
Tags
none
Rhea-AI Summary

Dyadic International, Inc. (NASDAQ: DYAI) announced it will report its financial results for the year ended 2022 and host a corporate update on March 29, 2023, at 5:00 p.m. ET. The company, focused on innovative microbial platforms for protein production and biopharmaceuticals, has developed C1 and Dapibus™ technologies. These platforms aim to lower production costs and enhance the performance of vaccines and biologics. Dyadic's initiatives include advancing its COVID-19 vaccine candidate, DYAI-100, and expanding its pipeline of biologic products. Investors can tune into the live conference call via the provided webcast link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
conferences earnings
-
Rhea-AI Summary

Dyadic International has completed dosing for all participants in its Phase 1 clinical trial of the DYAI-100 COVID-19 booster vaccine candidate. No serious adverse events have been reported, indicating a favorable safety profile thus far. This trial aims to assess both the safety and antibody response from the vaccine, produced using Dyadic's innovative C1-cell protein production platform. Results are anticipated in Q2 2023, with a comprehensive study report expected in the second half of the year. The study's success could enhance interest and adoption of Dyadic's technology across various sectors, including academic and governmental organizations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.86%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Dyadic International, a biotechnology company listed on NASDAQ under the symbol DYAI, announced participation in key investor and industry events in March 2023. Notable engagements include the 16th European Conference on Fungal Genetics and the 35th Annual Roth Conference. The company’s innovative microbial platforms aim to meet the rising demand for affordable biopharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.49%
Tags
conferences
Rhea-AI Summary

Dyadic International, a biotechnology company, announced that CEO Mark Emalfarb will participate in two investor conferences: the BIO CEO & Investor Conference on February 6, 2023, in New York, and the 35th Annual Roth Conference from March 12-14, 2023, in California. Emalfarb is available for one-on-one meetings during these events. Dyadic focuses on innovative microbial platforms for protein bioproduction and biopharmaceuticals, including its lead asset, the DYAI-100 COVID-19 vaccine candidate. The company aims to enhance access to affordable health solutions globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
conferences
-
Rhea-AI Summary

Dyadic International has initiated dosing in its Phase 1 clinical trial for the DYAI-100 COVID-19 booster vaccine candidate. This trial, conducted in South Africa, aims to evaluate the vaccine's clinical safety and antibody response in healthy volunteers aged 18-55. Following regulatory approval from SAHPRA in late 2022, the trial will consist of 15 subjects per cohort with a total randomization scheme of 4:1. Dosing is expected to complete within the first quarter of 2023, with results projected later this year. This marks the first human trial utilizing Dyadic’s C1 protein production platform, highlighting potential advancements in COVID-19 vaccine development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Dyadic International, Inc. (NASDAQ: DYAI) announced a receipt of approximately $1.27 million from the sale of its equity interest in Alphazyme LLC. This investment came as part of a licensing agreement whereby Dyadic granted a non-exclusive license to its technology. The agreement allows Dyadic to receive milestone and royalty payments from Alphazyme's sales of C1 expressed products, plus potential additional payments based on future sales of Alphazyme's existing products. Dyadic is focused on biopharmaceutical innovations for human and animal health, leveraging its C1-cell technology and other platforms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
none
Rhea-AI Summary

Dyadic International will participate in the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12, 2023, in San Francisco, CA. CEO Mark Emalfarb will present on January 8, focusing on advancements in Dyadic's C1-cell protein expression platform and its first Phase 1 clinical trial, expected to commence this month. Emalfarb will discuss the efficacy of C1-produced COVID-19 ferritin nanoparticle vaccines, supported by data from respected institutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences

FAQ

What is the current stock price of Dyadic International (DYAI)?

The current stock price of Dyadic International (DYAI) is $1.75 as of December 20, 2024.

What is the market cap of Dyadic International (DYAI)?

The market cap of Dyadic International (DYAI) is approximately 57.4M.

What does Dyadic International, Inc. do?

Dyadic International, Inc. specializes in gene expression technology, primarily utilizing its C1 Expression System for producing industrial enzymes and proteins.

What is the C1 Expression System?

The C1 Expression System is Dyadic's patented technology based on the Thermothelomyces heterothallica fungus, used for large-scale protein production.

Who are Dyadic's partners?

Dyadic partners with companies like Abengoa Bioenergy, BASF, and Codexis for various industrial applications of its technology.

What sectors does Dyadic serve?

Dyadic's technology serves multiple sectors, including pharmaceuticals, food, nutrition, wellness, human and animal vaccines, and therapeutics.

How does Dyadic's C1 Expression System benefit the healthcare sector?

The C1 Expression System helps produce vaccines and drugs faster, in greater volumes, and at lower costs, improving healthcare accessibility and affordability.

Where is Dyadic International, Inc. headquartered?

Dyadic International, Inc. is headquartered in Jupiter, Florida, USA.

What recent projects is Dyadic working on?

Dyadic is currently focusing on expanding the application of its C1 Expression System in the pharmaceutical industry for vaccine and therapeutic production.

How can I contact Dyadic for more information?

You can contact Ping W. Rawson, Chief Financial Officer, at (561) 743-8333 or via email at ir@dyadic.com.

What is Dyadic's stock symbol?

Dyadic International, Inc.'s stock symbol is DYAI.

What is the main goal of Dyadic International, Inc.?

Dyadic aims to leverage its C1 Expression System to improve the efficiency and cost-effectiveness of biologic vaccine and drug production, ultimately saving lives.

Dyadic International, Inc.

Nasdaq:DYAI

DYAI Rankings

DYAI Stock Data

57.40M
20.63M
30.21%
16.01%
0.61%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
JUPITER